52-Week Price Spotter: Tracking Shares of Novus Therapeutics, Inc. (:NVUS)

Shares of Novus Therapeutics, Inc. (:NVUS) have rallied over the past year. After a recent scan, we can see that the stock has posted a gain of 31.75% over that period of time. Investors will be intently watching to see if shares will continue to charge forward over the next 52-weeks.

Investors are often faced with difficult decisions when trading the equity market. Sometimes, the decision to sell a certain stock may be just as important as the decision to buy the stock in the first place. Individual investors may have done the research, had some good fortune, and are now dealing with a big winner in the portfolio. Even though a stock has had a big run, it may be time to unload and take some profits. Holding on to a winner too long can eat into profits that may have been better spent getting into another promising name. On the flip side, investors may have trouble letting go of an underperforming portfolio loser. The emotional attachment to a stock can cause the investor to hold onto a stock for way too long. Maybe the stock was thoroughly researched, but it just keeps going lower. Being able to cut the ties instead of waiting for a bounce back may be beneficial for portfolio health in the long run.

Novus Therapeutics, Inc. (:NVUS) currently has a beta of 3.54. A beta of 1 indicates that the stock price moves along with the market. A beta below 1 indicates that the stock is less volatile than the market in theory. A beta value over one would indicate the opposite. Conducting standard fundamental stock analysis is typically straightforward. Nowadays, investors have quick access to large amounts of information. The biggest stumbling block for the average investor may be devoting the time to actually accomplish the task. One goal of following the fundamentals is to establish the true value of a particular stock compared to how it is currently trading. Many investors think that identifying quality stocks should be a cornerstone of a solid portfolio build.

Following some sell-side analyst opinions on shares of Novus Therapeutics, Inc., we can see that the current consensus price target is $10.13. Analysts often work hard to provide their best estimates of where they think a stock is headed. Analysts may use different methods to calculate price targets, and investors often track the consensus to get a general feel of how the Street sees the stock.

Investors might be looking at various types of stocks that can be added to the portfolio. Selecting a wider range of equities may help the portfolio withstand prolonged market turmoil. Growth stocks typically have the potential to produce profit growth and above average revenues. Growth companies may reinvest a large amount of earnings back into the business. Fast growing companies can be attractive, but it may be important to verify whether or not shares are valued properly before buying in. Some investors may choose to select cyclical stocks. Cyclicals include companies that are very sensitive to the overall swings of the economy. Investors might also turn to adding foreign stocks to the portfolio. Keeping the portfolio diversified may end up being an important factor for longer-term investing success.

Checking on some performance metrics, we can see that Novus Therapeutics, Inc. (:NVUS) shares have seen a change of -7.92% over the last week. For the previous month, the stock has performed 88.60%. For the last quarter, the stock has performed 5.13%. If we look back year-to-date, the stock has performed 168.75%. Gathering as much knowledge as possible about a stock can help make the buying decisions a little less tricky. Some investors may trust professional opinions completely, but others may wish to dig in and do all the research themselves.

Figuring out when to exit a certain position can be just as important as deciding which stocks to buy in the first place. Many investors will end up holding onto a loser for far too long. The emotional attachment to a particular stock may keep the investor from making the decision to sell when necessary. On the other side of the coin, investors may hold onto a winner for way too long hoping for further gains. Investors may have to come up with a specific plan for what to do in these situations. Planning ahead may help ease the burden of making the tough portfolio decisions.